Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetic Testing Will Contribute To Growth In Drug Spending, Medco Predicts

Executive Summary

The growing prevalence of genetic testing as a clinical tool will drive increased drug spending and have a significant impact on medical practice, Medco predicts in its 2006 Drug Trend Report

You may also be interested in...

Personalized Medicine Will Not Destroy Blockbuster Model – Pfizer Exec

The move to personalized medicine will not put an end to the pharmaceutical blockbuster model, Pfizer Senior VP-Science & Technology Peter Corr said May 16

Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says

Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested

Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says

The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts